Cue Biopharma, Inc. CUE

US Biotechnology
$19.81 โ–ผ -1.64% ($-0.33)
🎈 Low Float 🎢 High Beta 📅 Earnings This Week
Open $19.74
Prev Close $20.14
Day Range $19.30 โ€“ $20.36
52W Range $4.97 โ€“ $45.50
Market Cap $146.31M
Beta 2.90
EPS (TTM) $-26.99

๐Ÿ“‹ Company Profile

IndustryBiotechnology
CountryUS
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD
IPO Date2018-01-02
Shares Out.7,260,000
Websitecuebiopharma.com/ โ†—
Phone13026587581
Employees29
Revenue$7.9M
Gross Profit$7.9M
Net Income-$153.1M
Free Cash Flow-$50.2M
Total Assets$30.7M
Total Liabilities$28.4M
Equity$2.3M
About Cue Biopharma, Inc.

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Cue Biopharma, Inc. is a publicly traded company under the ticker symbol CUE on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.

๐Ÿ“Š Analyst Ratings

6 analysts (2026-11-01)

Strong Buy 2
Buy 3
Hold 1

๐Ÿ“ฐ Latest News for CUE

๐Ÿ‘ฅ Related Stocks